Lexeo’s Gene Therapy Shows Early Promise for Friedreich’s Ataxia Cardiomyopathy

Lexeo Therapeutics’ investigational gene therapy reduces left ventricular volume and wall thickness in patients with Friedreich’s ataxia, according to a small study.